KR20170005415A - 과수면증의 치료 방법 - Google Patents

과수면증의 치료 방법 Download PDF

Info

Publication number
KR20170005415A
KR20170005415A KR1020167031237A KR20167031237A KR20170005415A KR 20170005415 A KR20170005415 A KR 20170005415A KR 1020167031237 A KR1020167031237 A KR 1020167031237A KR 20167031237 A KR20167031237 A KR 20167031237A KR 20170005415 A KR20170005415 A KR 20170005415A
Authority
KR
South Korea
Prior art keywords
ptz
subject
administered
sleep
gaba
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020167031237A
Other languages
English (en)
Korean (ko)
Inventor
린든 리엔
Original Assignee
밸런스 테라퓨틱스 인크.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 밸런스 테라퓨틱스 인크. filed Critical 밸런스 테라퓨틱스 인크.
Publication of KR20170005415A publication Critical patent/KR20170005415A/ko
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Neurosurgery (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
KR1020167031237A 2014-04-15 2015-04-14 과수면증의 치료 방법 Ceased KR20170005415A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201461979918P 2014-04-15 2014-04-15
US61/979,918 2014-04-15
PCT/US2015/025696 WO2015160766A1 (en) 2014-04-15 2015-04-14 Methods for treating hypersomnia

Publications (1)

Publication Number Publication Date
KR20170005415A true KR20170005415A (ko) 2017-01-13

Family

ID=54324484

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020167031237A Ceased KR20170005415A (ko) 2014-04-15 2015-04-14 과수면증의 치료 방법

Country Status (12)

Country Link
US (3) US10688103B2 (https=)
EP (1) EP3131904A4 (https=)
JP (2) JP6672264B2 (https=)
KR (1) KR20170005415A (https=)
CN (1) CN106459066B (https=)
AU (2) AU2015247829B2 (https=)
CA (1) CA2945705A1 (https=)
EA (1) EA201692061A1 (https=)
IL (1) IL248255A0 (https=)
MX (1) MX2016013340A (https=)
WO (1) WO2015160766A1 (https=)
ZA (1) ZA201607068B (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10278977B2 (en) 2016-06-06 2019-05-07 Umecrine Cognition Ab Methods for treating hypersomnolence
WO2018209119A1 (en) * 2017-05-10 2018-11-15 Emory University Treatment of conditions associated with myotonic dystrophy

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006137746A (ja) * 2004-10-13 2006-06-01 Otsuka Pharmaceut Factory Inc オレキシン誘導組成物
ES2573733T3 (es) 2006-05-22 2016-06-09 The Board Of Trustees Of The Leland Stanford Junior University Tratamiento farmacológico del deterioro cognitivo
US20110038850A1 (en) 2007-01-05 2011-02-17 Didier Bagnol G Protein-Coupled Receptor and Modulators Thereof For The Treatment of Gaba-Related Neurological Disorders Including Sleep-Related Disorders
US9616070B2 (en) * 2008-03-12 2017-04-11 Emory University Use of GABAA receptor antagonists for the treatment of excessive sleepiness and disorders associated with excessive sleepiness
US20090325999A1 (en) * 2008-06-27 2009-12-31 Jie Du Personalized pharmaceutical kits, packaging and compositions for the treatment of allergic conditions
US8946206B2 (en) * 2010-12-17 2015-02-03 The Board Of Trustees Of The Leland Stanford Junior University Methods for improving cognitive function
EP2678320B1 (en) 2011-02-23 2018-09-19 Coeruleus Ltd. Flumazenil complexes, compositions comprising same and uses thereof
CA2835018C (en) 2011-05-04 2020-04-21 Balance Therapeutics, Inc. Pentylenetetrazole derivatives

Also Published As

Publication number Publication date
EP3131904A1 (en) 2017-02-22
EA201692061A1 (ru) 2017-03-31
JP6672264B2 (ja) 2020-03-25
JP2020105200A (ja) 2020-07-09
IL248255A0 (en) 2016-11-30
CA2945705A1 (en) 2015-10-22
AU2019268190A1 (en) 2019-12-12
CN106459066A (zh) 2017-02-22
ZA201607068B (en) 2023-01-25
JP2017511386A (ja) 2017-04-20
EP3131904A4 (en) 2017-11-22
CN106459066B (zh) 2020-07-07
WO2015160766A1 (en) 2015-10-22
US20200360398A1 (en) 2020-11-19
MX2016013340A (es) 2017-02-09
AU2015247829A1 (en) 2016-10-27
AU2015247829B2 (en) 2019-12-05
US10688103B2 (en) 2020-06-23
US20230115839A1 (en) 2023-04-13
US20180169107A1 (en) 2018-06-21

Similar Documents

Publication Publication Date Title
US11648232B2 (en) Methods and compositions for treating excessive sleepiness
US20060252761A1 (en) Augmentation of extinction via administration of sub-antimicrobial doses of D-cycloserine
AU2018383098B2 (en) Cyclobenzaprine treatment for agitation, psychosis and cognitive decline in dementia and neurodegenerative conditions
Winkelman et al. Current patterns and future directions in the treatment of insomnia
US20230115839A1 (en) Methods For Treating Hypersomnia
KR20230004670A (ko) 다리도렉산트의 의학적 용도
WO2026085384A1 (en) Methods of treating essential tremor
KR20250165616A (ko) 고함량 단일 투여 단위 제형 및 이의 사용 방법
EA051790B1 (ru) Композиция кофеина с пульсирующим высвобождением
HK40112834A (zh) 用於痴呆和神经变性病况中的激越、精神病和认知衰退的环苯扎林治疗
Barbera et al. 30 Zaleplon
CA2665710A1 (en) Ih channel inhibitors for the promotion of wakefulness
CN101827597A (zh) 睡眠障碍的治疗
Barbera et al. Zaleplon

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20161108

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20200410

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20211028

Patent event code: PE09021S01D

E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20220422

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20211028

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I